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Background: The aim of this retrospective study was to define clinical and pathological 
features and prognostic factors among children and adolescents diagnosed with high-
grade osteosarcoma of the extremities.
Methods: A total of 73 patients younger than 18  years diagnosed with primary 
osteosarcoma of the extremities between January 1998 and December 2013 were 
retrospectively evaluated. Prognostic factors, such as age, gender, primary tumor site, 
alkaline phosphatase and lactate dehydrogenase levels, metastatic disease, pathological 
fracture, histological response, and surgery type, were analyzed to evaluate their effects 
on overall survival (OS) and event-free survival (EFS).
results: At a median follow-up of 30 months (1.5–152), OS and EFS at 5 years were 
64.5 ± 8.1 and 48.5 ± 8.7% for patients with localized disease; and 16.2 ± 7.9 and 
14.4 ±  7.3% for patients with initial metastatic disease, respectively. In patients with 
localized disease, conservative surgery was performed on 22 of 46 patients (43.5%), 
and there was no significant difference in survival rates among patients who had con-
servative vs. radical surgery (p = 0.65). Although tumor size (>12 cm) was significant 
prognostic factor in univariate analysis; multivariate analysis identified elevated levels 
of alkaline phosphatase (p = 0.033) and poor response to neoadjuvant chemotherapy 
(p < 0.001) only as independent prognostic factors. Age, histological type, pathological 
fracture, and primary tumor site did not significantly affect prognosis.
conclusion: Initial elevated presence of alkaline phosphatase in serum and poor histo-
logical response after neoadjuvant chemotherapy were significant factors for unfavorable 
prognosis. It is necessary to optimize staging and treatment intensification to improve 
survival rates, especially among patients with metastasis at initial presentation.
Keywords: osteosarcoma, children, prognostic factors
inTrODUcTiOn
Osteosarcoma is the most frequent malignant bone tumor at pediatric age. Surgical removal of the 
tumor remains the most important treatment; however, survival rates have increased due to the 
advent of chemotherapy (1–3). In prospective studies, 5-year event-free survival (EFS) rates between 
55 and 75% have been reported (4–6), and recurrence occur approximately 30–40% of patients with 
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localized disease, in spite of complete surgical resection of pri-
mary tumor and an intense regimen of chemotherapy (7). These 
findings reveal an important need to clarify prognostic factors for 
recurrence or poor survival.
Currently, several studies have already identified clinical 
or pathological features associated with worse outcome. Some 
published data contain a reduced but homogeneous number of 
cases of limited statistical significance (8, 9). Moreover, multi-
center research studies differ in data collection and therapeutical 
schemes (10–13), which makes it difficult to compare and reveals 
contradictory results.
In our region, there are no published studies defining prog-
nostic factors for osteosarcoma, which is essential to improve 
the development of new and adapted strategies according to risk 
groups so as to improve survival rates.
The aim of the present study is to define clinical and pathologi-
cal features and prognostic factors related to survival rates among 
pediatric patients diagnosed with high-grade osteosarcoma of the 
extremities in our country.
MaTerials anD MeThODs
Patients
Seventy-three patients diagnosed with primary high-grade osteo-
sarcoma of the extremities (both localized and metastatic) were 
retrospectively evaluated. All patients were treated at the Pediatric 
Oncology Unit of the Rebagliati Hospital in Lima, Peru between 
January 1998 and December 2013. All patients who received chem-
otherapy and surgical treatment in our hospital were included.
Diagnostic Methods and staging
Plain X-rays and CT scans or MRI of the primary tumor were 
performed at the time of diagnosis, prior to surgery, and at the end 
of therapy. Chest CT scan and bone scintigraphy were performed 
to detect distant metastases. All patients underwent confirma-
tory biopsy (open or by tru-cut needle) in our institution, and 
the diagnosis was confirmed by conventional light microscopy 
(histology). All cases of high-grade osteosarcoma were included 
(conventional, telangiectatic, fibroblastic, and small cell subtype). 
Patients with low grade tumors, such as parosteal osteosarcoma, 
were excluded.
systemic Treatment
After diagnosis and staging, the patient started neoadjuvant 
chemotherapy. Seventy-one patients (97.3%) received chemo-
therapy based on SEOP-95 consisted of high-dose methotrexate at 
12 g/m2 per cycle with leucovorin rescue for 11 cycles, adriamycin 
at 75 mg/m2 per cycle for 6 cycles, cisplatin at 120 mg/m2 per cycle 
for 2 cycles. Additionally, ifosfamide at 9  g/m2 was used for six 
cycles. Length of chemotherapy treatment was 37 weeks. Definitive 
surgery was scheduled on week 15. A chemotherapy regimen 
without methotrexate (OS99) was used in two patients due to renal 
toxicity secondary to methotrexate (after two cycles on the previous 
regimen). Neoadjuvant chemotherapy treatment was lengthened 
(n = 4) or shortened (n = 2) in six patients (8.3%) due to problems 
related to social security coverage or availability of prosthesis.
local Treatment
The first definitive surgical treatment was documented as 
conservative (resection of primary tumor) with or without endo-
prosthesis (n =  31); or radical (amputation or disarticulation) 
(n = 42). Surgery type and reconstruction were decided accord-
ing to tumor site and extension, patient’s age, and presence of 
compromised neurovascular structures.
statistical analysis
Data about time from first symptoms to beginning of therapy, age, 
gender, primary tumor site, initial alkaline phosphate (AP) and 
lactate dehydrogenase (LDH) levels, metastatic disease at onset, 
presence of pathological fractures, histological response or necro-
sis after completion of neoadjuvant chemotherapy (<90% and 
more or equal to 90%) (14, 15), and type of surgery were evalu-
ated. SPSS 22.0 Statistics was used (SPSS Corp., USA). Overall 
survival (OS) was defined as the time from diagnosis to death 
from any cause and EFS was defined as the time from diagnosis to 
treatment failure, secondary neoplasm, or death, whichever came 
first. Patients who did not suffer an event were sensored at the 
time of last follow-up. OS and EFS rates were analyzed, accord-
ing to Kaplan–Meier curves. A multivariate Cox proportional 
hazards regression analysis was performed to determine which 
parameters were significant. A 95% confidence interval level was 
used; being a p < 0.05 was considered significant.
ethical considerations
Our study was not set up as a study or research project; hence, 
we did not seek informed consent or ethical committee approval 
due to it does not report on primary research. Absolutely, all data 
analyzed were collected as part of routine diagnosis and treat-
ment, and all patients were diagnosed and treated according to 
institutional guidelines and agreements. All laboratory tests (as 
well as recording all other variables included in our analysis) 
are essential for confirming diagnosis and classifying patients, 
and they are done for each patient without fail and as part of 
routine care. Moreover, this paper does not report on the use of 
experimental therapies. We looked retrospectively at outcomes 
for a long-term cohort of patients treated as a process of an audit/
evaluation, so as to improve our quality of care.
resUlTs
Patient characteristics
A total of 73 patients under 18 years of age were included. Patient 
characteristics are listed in Table 1. The mean age at diagnosis 
was 14  years (range, 5–17  years). Sixty-six percent of patients 
were male (45 patients). Average length of follow-up period 
was 30 months (1.5–152 months). There was metastatic disease 
at initial presentation in 27 patients (37%), being the lungs the 
most commonly affected organ (24 patients), followed by bone 
metastases (3 patients). Latency time from manifestation of the 
first symptoms and the beginning of treatment was 4.3 months on 
average, with a range of 0.3–19 months.
In the localized group, conservative surgery was performed 
in 22 out of 46 patients (47.8%), and no significant difference was 
TaBle 1 | Demographic and clinical characteristics (N = 73).
characteristic number of patients (%)
Male (n, %) 45 (61.6%)
Age at diagnosis (years)
 Mean 14
 Range 5–17
Histological subtype
 Osteoblastic 52 (71.3%)
 Chondroblastic 12 (16.4%)
 Telangiectatic 5 (6.8%)
 Fibroblastic 3 (4.1%)
 Other 1 (1.4%)
Location of tumor
 Distal femur 33 (45.2%)
 Proximal tibia 15 (20.5%)
 Proximal femur 10 (13.7%)
 Humerus 9 (12.3%)
 Fibula 6 (8.3%)
Distant metastases at onset
 Yes 27 (37%)
 No 46 (63%)
Histological response (n = 40)
 ≥90% 21 (52.5%)
 <90% 19 (47.5%)
Elevated serum AP 58 (79.5%)
Elevated serum LDH 57 (78.1%)
Type of surgery
 Conservative 31 (42.5%)
 Amputation 42 (57.5%)
Tumor size (n = 32)
 ≤12 cm 25 (78.1%)
 >12 cm 7 (21.9%)
TaBle 2 | summary of univariate cox proportional hazards model for 
overall survival.
Variables Univariate 
lrT
hr  
(95% ci)
Multivariate 
lrT
hr  
(95% ci)
p-Values p-Values
Male gender 0.78 1.14 (0.44–2.94)
Age, <10 years 0.09 3.73 (0.42–2.47)
Histological 
subtype
0.96 1.02 (0.15–6.64)
Location of 
tumor
0.57 0.77 (0.31–1.94)
Initial 
metastases
<0.01 4.88 (3.48–40.57) <0.01 4.6 
(3.71–38.93)
Necrosis >90% <0.01 0.08 (0.02–0.31) <0.01 0.13 
(0.06–0.28)
Tumor size 
>12 cm
<0.01 4.01 (2.43–8.12) 0.058 3.5 
(0.92–9.39)
Initial raised ALP 0.027 3.90 (1.11–13.71) 0.033 3.1 
(1.10–5.27)
Initial raised 
LDH
0.18 2.13 (0.63–6. 67)
Pathological 
fracture
0.30 1.86 (0.56–6.22)
LRT, likelihood ratio test; HR, hazards ratio; CI, confidence interval.
Significant variables (p values <0.05) are in bold.
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observed in survival rates related to type of surgery (p = 0.65). 
In both groups (localized and metastatic), radical surgery 
(amputation or disarticulation) was performed in 42 cases, and 
limb-preservation surgery (with or without endoprosthesis) 
was done on 31 patients. Patients with localized disease had 
better chances of having conservative surgery compared to 
those with metastatic disease at presentation (p = 0.003) (47.8 
vs. 25.9%).
Twenty-three patients (31.5%) had recurrent disease (3 local 
and 20 metastatic). In 19 cases (82.6%), recurrence occurred 
within the first 3 years of diagnosis. Initial treatment was surgi-
cal if recurrence was local (three patients), with amputation in 
two cases and tumor resection in one patient. These patients 
received second-line chemotherapy (etoposide or carboplatin 
based). Only the patient who had tumor resection surgery had 
no evidence of disease for 42  months, whereas the other two 
died from progressive disease. Treatment in case of metastatic 
recurrence (20 patients) was surgical in 13 cases (65%) (lung 
metastasectomy, bilateral, when possible) or second-line 
systemic chemotherapy alone in 7 cases (35%) in case surgery 
was not possible (due to irresectable tumor or multiple lung 
nodules), presence of distant lesions in the liver and brain, or 
refusal to surgery. Nine of 20 patients (45%) died from progres-
sive disease. In two cases of metastatic pulmonary relapse, after 
surgical resection of lung metastases, high-dose chemotherapy 
was administered and autologous stem cell transplant was 
performed. In one of those two cases, the patient died from 
progressive of disease, and the other had a complete remission 
with a follow-up of 6 years.
Prognostic Factors for Overall survival
Univariate and multivariate analysis of factors predicting treat-
ment failure is shown in Table 2. An initial elevated serum level 
of AP (p = 0.027), poor histological response (necrosis of <90%) 
(p < 0.01), large tumor size (>12 cm) (p < 0.01), and metastatic 
disease (p < 0.01) was statistically significant for worse survival. 
All these variables except tumor size remained significant on 
multivariate analysis.
Gender, age, initial LDH levels, presence of pathological 
fracture, histological subtype (osteoblastic, chondroblastic, 
telangiectatic or fibroblastic), latency time of symptoms, primary 
site tumor, and type of surgery were not significant for survival in 
univariate or multivariate analysis.
Surgical margins were compromised in two patients (2.8%) 
who had metastasis at initial presentation and underwent limb 
amputation after neoadjuvant chemotherapy. Both died due to 
progressive disease. No statistical analysis was performed due to 
small number of patients.
Some patients had an alteration in the neoadjuvant chemo-
therapy sequence (it was either longer or shorter) due to problems 
with health insurance or with availability of prosthesis. There 
was no statistical difference with respect to those who received 
standard therapy.
Os and eFs
Overall survival and EFS at 5 years was 64.5 ± 8.1 and 48.5 ± 8.7% 
for the localized group, and 16.2 ± 7.9 and 14.4 ± 7.3% for the 
metastatic group, respectively (Figures 1 and 2).
FigUre 2 | event-free survival of patients with localized and 
metastatic osteosarcoma of extremities (N = 76).
FigUre 1 | Overall survival of patients with localized and metastatic 
osteosarcoma of extremities (N = 76).
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DiscUssiOn
Identifying prognostic factors in osteosarcoma patients is vital to 
define risk groups. A number of clinical and pathological vari-
ables, such as histological subtype, age, gender, elevated levels of 
AP or LDH, and genetic variations have been previously studied 
with prognostic significance, but often with contradictory results 
due to lack of homogeneity in analysis and methods. In a system-
atic revision of prognostic factors for osteosarcoma, it was found 
that histological response, presence of metastasis, and primary 
tumor size and site were important prognostic factors (16).
Our study found considerably higher incidence of clinically 
detectable metastatic disease at initial presentation when com-
pared to expected rates in developed countries (10–20%) (17–19), 
or even when compared to other Latin American studies, like 
those done in Brazil (20.8%) (5, 20, 21), being almost 40%. This 
is probably due to delay in diagnosis and advanced disease at 
the moment of diagnosis, and it turns out to be the first cause 
of mortality among these patients, which makes it a significant 
prognostic factor, as reported by prior studies (5, 6).
As previously described (17), presence of pathological 
fractures ranges from 7 to 18% (in our study 14%) and, while 
it did not proof to be prognostic as reported earlier (22), it is an 
important indicator of late diagnosis in our cases.
Age has been identified as a prognostic factor for osteosar-
coma. Patients under the age of 10 (18) or 12 years (9) have poorer 
survival rates in some reports, which suggest aggressive behavior 
of this disease in small children. Nevertheless, more recent stud-
ies have failed to confirm the latter (13, 19), and we have also not 
observed this in our study. In a recent study, patients with age 
above 40 years also carried a dismal prognosis (23).
Gender was not prognostic, as has already been mentioned 
in European (13, 18) and American report studies (9). However, 
Brazilian (20) and Scandinavian (24) studies have included 
observations about female gender having a better prognosis.
The present study has not found any significant difference in 
survival rates according to histological subtype, as previously 
reported (25). According to other authors, there is evidence of 
lower risk of recurrence in fibroblastic and telangiectatic subtypes 
(26). It has also previously been mentioned that the chondro-
blastic subtype could be the one with the best prognosis (27). 
Furthermore, histological response has been more favorable in 
fibroblastic and telangiectatic groups, and less favorable in the 
chondroblastic group (28).
Prior studies have revealed that surgery type (radical vs. 
conservative) in patients with high-grade non-metastatic osteo-
sarcoma does not affect survival or local recurrence rates (29–31). 
This is supported by our study, where no significant difference 
was found in both groups. In a study conducted by Bacci et al., 
560 non-metastatic osteosarcoma patients were examined, and 
no variation in survival rates was found when considering surgery 
types. The percentage of conservative surgery, even though it has 
increased over the years and is currently at 20% of total opera-
tions, is still lower than the rates published by other groups (5).
Degree of necrosis as histological response to neoadjuvant 
chemotherapy is currently considered the most important prog-
nostic factor in patients with high-grade osteosarcoma, according 
to reports in previous studies (5–7, 32). The percentage of patients 
who have a favorable response (≥90%) goes from 50 to 60% (32), 
whereas, it was 52.5% in our study.
The prognostic value of AP in osteosarcoma has previously 
been reported (9, 31, 32) and has been confirmed in our study. 
Bacci et  al. have reported that initial values of more than four 
times the normal level are linked to lower EFS rates (33).
Event-free survival rates among osteosarcoma patients 
worldwide are between 55 and 75%, which has not improved sig-
nificantly in recent years. Studies in developed countries mention 
survival rates of 70–75% in localized disease (4, 6, 34, 35). A study 
by the European group (COOS) done on 1702 patients found that 
there was 5-year OS of 63.3% and an EFS of 52.8% (34). A study 
from the Rizzoli Institute describes patients with localized disease 
at initial presentation with 10-year overall and EFS of 70 and 59%, 
respectively (4).
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Survival rates are considerably lower in metastatic disease, 
having an average of 10–40% patients alive long term. Meyers 
et al. (36) reported that only 11% of 64 patients survived, with 
an average length of 20  months. Kager et  al. (37) described a 
5-year overall and EFS in 202 patients of 29 and 18%, respectively. 
Similar reports have been done by European groups with 16% 
rates (n = 45) and by American groups with 53% rates (n = 30), 
the latter study having important differences, such as a higher 
proportion of patients with unique lung metastases and excluding 
patients with irresectable disease (38, 39). In Peru, there are no 
previous reports about survival in osteosarcoma patients. Our 
results showed overall and EFS rates comparable to studies in 
developing countries (40–42).
The present study has its main limitation on the small number 
of patients. Similarly, there is missing information in some of 
the cases, due to its retrospective design, which encourage us to 
standardize and improve clinical records in our institution.
Nevertheless, its main strength is that it represents a first analy-
sis of its kind in the medical literature of our country and blazes a 
trail for more ambitious and wider ranging future studies.
cOnclUsiOn
The presence of initial serum elevated AP levels and a poor 
histological response after neoadjuvant chemotherapy were 
significant predictors in children with osteosarcoma of 
extremities. Therefore, it reveals the need for cooperative 
studies that outline strategies on the basis of risk factors. It 
is necessary to optimize staging and intensification of treat-
ment to improve survival rates, especially among patients 
with metastases at initial presentation.
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